NIH, FDA Respond To SARS Epidemic: Diagnostics, Medical Supply Stockpile
This article was originally published in The Gray Sheet
Executive Summary
A sensitive and specific diagnostic for severe acute respiratory syndrome will be available in six to 12 months, NIAID Director Anthony Fauci, MD, averred at a May 7 House Energy & Commerce/Oversight & Investigations Subcommittee hearing
You may also be interested in...
Industry, FDA Coordination Key To Diagnostic Test Availability – McClellan
FDA and CDC will coordinate efforts to provide standardized specimens of severe acute respiratory syndrome (SARS) to manufacturers by year-end to aid in validating diagnostics for the disease
Industry, FDA Coordination Key To Diagnostic Test Availability – McClellan
FDA and CDC will coordinate efforts to provide standardized specimens of severe acute respiratory syndrome (SARS) to manufacturers by year-end to aid in validating diagnostics for the disease
SARS Test Available From CDC Within Weeks; Mutations May Hinder Diagnosis
CDC remains cautious about the viability of a SARS diagnostic, citing the coronavirus' proclivity for mutations that may threaten performance of polymerase chain reaction (PCR) and antibody tests